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A host of innovative diagnostic and disease monitor-
ing methods have been used to assess disability and 
responses to targeted therapies for individuals with 
multiple sclerosis (MS). One of the most commonly 
used measures of disability is the Expanded 
Disability Status Scale (EDSS).1 While comprehen-
sive, the EDSS score has been criticized by some for 
suboptimal inter-rater reliability, marginal sensitiv-
ity to change in disability, a bias towards locomotor 
function,2–5 as well as the need for a trained neurolo-
gist for valid scoring.2 In some instances the timed 
25-foot walk test has been used alone to assess dis-
ease progression6 as opposed to the EDSS score.
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Abstract
Objective: The purpose of this study was to determine if there is a practice effect present in the timed 
25-foot walk in ambulatory individuals with multiple sclerosis.
Design: Thirty six people (30 women and 6 men) diagnosed with relapsing remitting multiple sclerosis 
participated in two testing sessions, one week apart. Each participant performed two sequential trials 
of the timed 25-foot walk test per session and the walk performance was measured with a laser timing 
system.
Results: We observed improvements in walking speed between the two trials of session one (trial one: 
6.42 (0.09) vs. trail two: 5.97 (0.08) seconds, p < 0.001). Within session two, performance remained 
stable (trial three: 5.71 (0.07) vs. trial four: 5.63 (0.07) seconds, p > 0.05). We also observed a significant 
improvement in walking speed when averages of the two trials were compared across sessions (session 
1: 6.19 (0.09) vs. session 2: 5.67 (0.07) seconds, p < 0.01).
Conclusions: Based on our results, familiarization of the timed 25-foot walk test improves stability of 
walk performance scores in ambulatory individuals with relapsing remitting multiple sclerosis.
Keywords
Multiple sclerosis, assessment, clinical tests, mobility, repeatability
Received: 19 June 2012; accepted:  10 November 2012
Article
 at UNIV OF OKLAHOMA on January 20, 2016cre.sagepub.comDownloaded from 
720 Clinical Rehabilitation 27(8)
The National Multiple Sclerosis Society appointed 
Task Force on Clinical Outcomes Assessment rec-
ommended a new approach in assessing clinical out-
come measures, which lead to the development of the 
Multiple Sclerosis Functional Composite (MSFC) 
score.7–9 The MSFC test includes quantitative assess-
ments of arms/hand function (Nine-hole Peg Test), 
cognitive function (Three-second Paced Auditory 
Serial Test) and leg function/ambulation (timed 
25-foot walk test)) with performance scores averaged 
and transformed into z scores for comparison pur-
poses.7,9,10 There appears to be a practice effect of the 
MSFC as evidenced by Cohen and colleagues and 
Fischer et al. that lead to the recommendation that the 
MSFC test should be administered with a pre-base-
line testing session to familiarize the subjects and 
examiners with the testing protocol.9,11 Despite these 
recommendations, test administration procedures 
have been inconsistent, with some researchers using 
only one or no pre-baseline measures.12–21 The lack 
of consistency in testing procedures provides the 
possibility of biasing test results, such that the change 
in walk speed might not arise from the intervention 
or treatment, but rather owing to a practice effect. 
Therefore, the purpose of this study was to determine 
if there is a significant practice effect present in the 
timed 25-foot walk test.
Methods
Participants
Thirty six volunteers (30 females and 6 males) with 
clinically stable relapsing remitting MS signed a writ-
ten informed consent approved by the University 
Institutional Review Board prior to study enrollment. 
Participants had an EDSS score < 6.5 (able to walk at 
least one city block), no orthopedic limitations or other 
health related issues that would preclude safe partici-
pation and no prior exposure to the test procedures.1
Study design and timed 25-foot walk 
procedures
This study involved making repeated measurements 
on two testing occasions. Study participants performed 
a total of four trials of the timed 25-foot walk test. 
Two sequential trials were performed during the ini-
tial test session and two trials were performed again, 
one week later, during a second test session. A digital 
timing system (Brower IRD-T175, Salt Lake City, 
Utah) was used to assess walk performance. The tim-
ing system included start and finish laser sensors that 
were positioned 91.4 centimeters (36 inches) apart, 
which is the width of a common doorway) and 38 
centimeters (15 inches) from the ground. All partici-
pants started in a standardized standing “start posi-
tion”, which was 12.7 centimeters (5 inches) behind 
the laser timing system. The timing system started 
and stopped when the participant broke the laser sen-
sor’s plane. Each participant received standard 
instructions that they all understood: “I’d like you to 
walk 25 feet as quickly as possible, but safely. Do not 
slow down until after you’ve passed the finish-line. 
Ready? Go”. The task was immediately administered 
for a second trial in the same manner as the first trial. 
The participants returned within one week at approxi-
mately the same time of day and performed the same 
test as before (session two). The recommended proce-
dures for scoring the timed 25-foot walk test are to 
take the average of two completed trials.10 The par-
ticipants were at no time advised of their performance 
scores from trial to trial.
Data analysis
All analyses were performed using SPSS software 
(SPSS Inc., Version 16. Chicago, IL). Repeated mea-
sures analysis of variance (ANOVA) were used to 
detect differences across the four trials (two trails on 
each of the two sessions) of the timed 25-foot walk 
test. Dependent t-tests were then used to compare dif-
ferences between trials if the F-test was significant. 
An alpha of 0.05 was used to establish statistical sig-
nificance. Additionally an intraclass correlation coef-
ficient was calculated to assess test-–retest reliability. 
To obtain the mean square values each participant had 
an average score for session one (trial one and trial 
two) and for session two (trial three and trial four).
Results
A total of 36 volunteers performed the timed 25 foot 
walk test (30 females and 6 males, 12 participants 
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had EDSS scores >4.5 and two participants used 
walking aids). Participants had a mean age, height, 
weight, body mass index and EDSS score of 45.2 
(1.8) years, 1.7 (0.02) meters, 82.4 (3.4) kilograms, 
28.4 (1.0) kg/m2, and 3.5 (0.4), respectively. 
Additionally they had low levels of physical activ-
ity with no more than two times per week of 15–30 
minutes of low to moderate intensity activities. 
Average walk times were significantly faster on 
trial two than on trial one (trial one: 6.42 (0.09) sec-
onds vs. trial two: 5.97 (0.08) seconds, p < 0.001). 
However, no significant differences were observed 
between trials two, three and four (trial two: 5.97 
(0.08) seconds vs. trial three: 5.7 (0.07) seconds, p 
> 0.05); (trail three: 5.71 (0.07) seconds vs. trial 
four: 5.63 (0.07) seconds, p > 0.05).
When trials within each session were averaged, we 
observed significantly faster walk times on the second 
testing session (session one: 6.19 (0.09) seconds vs. 
session two: 5.67 (0.07) seconds, p < 0.01). The intra-
class correlation coefficient (reliability) for the aver-
age of the two trials within a session was 0.92.
Discussion
The main findings of this study were: 1) significant 
improvements in timed 25-foot walk performance 
across the first two trials that were stabilized by the 
third trial; and 2) when using the current MSFC 
score recommendations of administering two trials 
and averaging the times, we observed significantly 
faster gait speeds during the second test session. Our 
findings are consistent with other reports that sug-
gest that improvements in timed 25-foot walk times 
might be associated with a practice effect.9 However, 
others have reported non-significant improvements 
in walk times during practice trials.22–23 Possible rea-
sons for the disparate findings may include: 1) par-
ticipant’s prior exposure to testing procedures; 2) 
participant variability (disease type and disability 
status) of symptoms; and/or 3) variability in 
researchers administrating the timed 25-foot walk 
test. Participants in our study reported no prior expe-
rience with the walk test procedures, which may 
help explain some of the discrepant findings between 
our results and other investigators, as practice has 
been shown to improve performance.11 Additionally, 
the observed practice effect seemed to persist over a 
one-week period. Some of our unpublished prelimi-
nary data further indicates that this practice effects 
persists after as long as six months.
The disability range of the participants in this 
study may help explain discrepancies in study out-
comes. Our study was limited to people with relaps-
ing remitting MS and an EDSS score of less than 
6.5. Reliability studies of the MSFC scores and the 
timed 25-foot walk test include a variety of partici-
pants with EDSS scores ranging from 0–8.0 and 
diverse types of disease status (relapsing remitting, 
primary progressive and secondary progres-
sive).9–11,24 The variability of samples could account 
for differences within and between studies. One 
way to determine test–retest reliability is through an 
intraclass correlation coefficient. At first glance, it 
appears that our data has very good reliability 
between sessions, R = 0.92. However, owing to the 
high variability between subjects, our reliability 
coefficient may have been inflated.
Finally, differences in administration and/or 
scoring of walking trials may contribute to dis-
similar findings between studies. For example, the 
recommended procedures for the MSFC is to 
administer the timed 25-foot walk test twice and 
reporting the average of the two trials, with no 
mention of a practice session, despite reference to 
reliability studies indicating practice session 
recommendations.9,11
In some instances, the lack of methodological 
details about test administration procedures makes 
it difficult to discern whether the results being 
reported reflect an individual’s true change in per-
formance ability. When comparing test administra-
tion procedures across studies, specific details of 
testing methods are not always described, leaving it 
unclear whether a practice session occurred or 
whether participants had previous experience with 
the test.11,22,23,25 In some instances, the timed 25-foot 
walk test was administered with one trial in a ses-
sion,19 whereas in another study, the test was per-
formed four times and the scores were averaged.20 
These variations in test administration procedures 
could account for some of the different findings 
observed between studies.
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Another complicating factor for the proper inter-
pretation of timed 25-foot walk test performance 
arises from the MSFC itself. The MSFC was origi-
nally developed utilizing z scores wherein an indi-
vidual performance score (x) minus the mean of the 
group (y) is divided is by standard deviation (SD) 
[(x–y)/(SD)]. There have been reliability and valid-
ity studies to assess the impact the practice effects 
have on z scores.9,22,25 In regards to the timed 25-foot 
walk test, the learning effect was found to be mini-
mal when using a z scores. This transformation 
could result in underreporting the absolute magni-
tude of the variability measures. For example, if an 
individual had a score of x = 7 seconds on trial 1 of 
the timed 25-foot walk test and the group mean of y 
= 5 seconds and SD = 2, the calculated z score is 1.0. 
If that same individual was retested and his/her 
walk time slowed to X = 10 seconds and the group 
mean shifted to Y = 8 seconds with a SD = 2, the 
calculated z score is still 1.0, but walk time was 
about 43% slower. If the timed 25-foot walk test is 
used as a measure of clinical differences, scores 
from the actual performance data are more appro-
priate and informative for statistical comparisons, 
because the treatment effects would affect the mag-
nitude of pre–post group means (y, Y).
In summary, the present study has demonstrated 
the practice effects of the timed 25-foot walk test, 
which appears to stabilize after two practice trials. 
There are discrepancies within the current body of 
literature regarding the impact of the practice effect. 
However, it is unclear what the magnitude of its 
impact is owing to many investigators not clearly 
describing their testing procedures. Based on our 
results, participant familiarization with timed 
25-foot walk test could improve stability of walk 
performance scores in individuals with MS. Thus 
there is a need for standardized instructions and pro-
duces that researches adhere to. Our findings high-
light new information relevant to administration of 
the timed 25-foot walk test; however, we appreciate 
limitations to our study, such as our limited sample. 
Our study also only tested participants with relaps-
ing remitting MS with an EDSS score < 6.5. 
Additional research is needed to specifically test 
across the different disease patters and with the 
inclusion of individuals with higher EDSS scores.
Clinical messages
 • Baseline 25-foot ambulation tests should 
include at least two practice trials.
 • Lack of familiarization with the 25-foot 
walk test can confound true performance 
improvements.
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